Document is current
Any future updates will be listed below
-
Authors
Niu, Nan
Li, Keyu
Wang, Junke
Funes, Vanessa
Espinoza, Birginia
Li, Pan
Wang, Jianxin
Lyman, Melissa
He, Mengni
Herbst, Brian
Wichroski, Michael
Novosiadly, Ruslan
Shoucair, Sami
Mou, Yiping
Zheng, Lei
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82303740)
Key Research and Development Project of Science and Technology Department of Sichuan Province (2023YFS0167)
China Postdoctoral Science Foundation (2023T160451)
West China Hospital Postdoctoral Science Foundation (2023HXBH053)
National Natural Science Foundation of China for Young Scientists Fund (82403318)
Sichuan Natural Science Foundation Youth Foundation Project (2024NSFSC1949)
NIH Grant (R01 CA169702)
NIH SPORE Grant (P50 CA062924)
NIH Cancer Center Support Grant (P30 CA006973)
- License Information
-
More Information
Article History
Received: 28 November 2024
Accepted: 27 December 2024
First Online: 27 January 2025
Declarations
:
: All studies and maintenance of mice were conducted in accordance with the approval of the Institutional Animal Care and Use Committee (IACUC) guidelines of Johns Hopkins School of Medicine (Animal Protocol: MO22M59).
: All authors participated in the writing of the manuscript. All authors agreed to the final version of the manuscript.
: L.Z. receives grant support from Bristol-Meyer Squibb, Merck, AstraZeneca, iTeos, Amgen, NovaRock, Inxmed, Halozyme and Abmeta. L.Z. is a paid consultant/Advisory Board Member at Biosion, Alphamab, NovaRock, Ambrx, Akrevia/Xilio, QED, Novagenesis, Snow Lake Capitals, Amberstone, Pfizer, Tavotek, and Mingruizhiyao. L.Z. holds shares at Alphamab, Amberstone, Mingruizhiyao, and Cellaration.
